Cervical cancer biomarker and test kit thereof

Abstract

The invention provides a cervical cancer biomarker. The cervical cancer biomarker comprises one or more of marker proteins stably present in a biological sample: DEPDC1, POLQ, MCM10, ASPM, TPX2, JPH4,CDC45, MYBL2, PAGE4, NCAPG, FOXM1, KIF20A, CDC20, NEK2, CASQ2, PRLHR, SLITRK3, HJURP, DLGAP5, TOP2A, MYH11, TROAP, SCN7A, CEP55, NUF2, CLVS2, MKI67, GPM6A, BUB1B, CD300LG, LMOD1, TCF23, CLEC3B, MELK, RRM2, EXO1, KIF18B, ADH1B, PEG3, TCEAL6, PGM5-AS1, ADAMTS9-AS2, CARMN, RP11-887P2.5, FR D6-AS2, FXYD1, LCN6, UHRF1, GPIHBP1 and AC053503.12. According to the invention, the marker protein selectedfrom the biological sample is used as a novel cervical cancer biomarker, which has the advantages of convenient material selection, low detection cost, good sensitivity and high specificity; through avariety of cervical cancer biomarkers, the defects of low specificity and low sensitivity caused by differences between individuals can be effectively overcome; and the diagnosis rate of a disease issignificantly improved. The invention further provides a cervical cancer biomarker test kit.

Description

technical field [0001] The invention belongs to the technical field of biological detection, in particular to a cervical cancer biomarker and a detection kit. Background technique [0002] Cervical cancer is a major health problem for women in the world. In 2012, the global incidence of cervical cancer was 528,000, and the annual death rate was 266,000. It is the most common cancer among women in the world, and 85% of cases occur in developing countries. Cervical cancer is The main cause of cancer death in women, the prognosis of patients with cervical cancer is closely related to the clinical stage, most patients with early stage cervical cancer can be successfully cured, but the survival rate of patients with advanced cervical cancer is only 15%, therefore, early diagnosis and treatment can Significantly reduce the mortality rate of cervical cancer patients, cervical smear cytology is the main screening method for early diagnosis of cervical cancer, but the shortcomings of...

AI Technical Summary

Problems solved by technology

[0002] Cervical cancer is a major health problem for women in the world. In 2012, the global incidence of cervical cancer was 528,000, and the annual death rate was 266,000. It is the most common cancer among women in the world, and 85% of cases occur in developing countries. Cervical cancer is The main cause of cancer death in women, the prognosis of patients with cervical cancer is closely related to the clinical stage, most patients with early stage cervical cancer can be successfully cured, but the survival rate of patients with advanced cervical cancer is only 15%, therefore, early diagnosis and treatment can Significantly reduce the mortality rate of cervical cancer patients, cervical smear cytology is the main screening method for early diagnosis of cervical cancer, but the shortcomings of inspection inconvenience and high false negative rate limit its application, in addition, in addition to cervical smear cytology In addition to examination, serum biomarkers are also commonly used in the diagnosis of cervical cancer, including carbohydrate antigen 125 (Carbohydrate Antigen 125, CA125) and squamous cell carcinoma antigen (Squamous Cellcarcinoma Antigen, SCC Ag), whose diagnostic sensitivity and specificity are still low limit its use, therefore, there is an urgent need for novel non-invasive biomarkers with high sensitivity and specificity for cervical cancer screening

Images